352 related articles for article (PubMed ID: 25791890)
1. The history of vaccination against cytomegalovirus.
Plotkin S
Med Microbiol Immunol; 2015 Jun; 204(3):247-54. PubMed ID: 25791890
[TBL] [Abstract][Full Text] [Related]
2. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
3. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
5. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
6. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
7. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.
Freed DC; Tang Q; Tang A; Li F; He X; Huang Z; Meng W; Xia L; Finnefrock AC; Durr E; Espeseth AS; Casimiro DR; Zhang N; Shiver JW; Wang D; An Z; Fu TM
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4997-5005. PubMed ID: 24297878
[TBL] [Abstract][Full Text] [Related]
8. A Fully Protective Congenital CMV Vaccine Requires Neutralizing Antibodies to Viral Pentamer and gB Glycoprotein Complexes but a pp65 T-Cell Response Is Not Necessary.
Choi KY; McGregor A
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452332
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.
Choi KY; El-Hamdi NS; McGregor A
Vaccine; 2020 Feb; 38(10):2340-2349. PubMed ID: 32008881
[TBL] [Abstract][Full Text] [Related]
10. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
[TBL] [Abstract][Full Text] [Related]
11. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.
Cardin RD; Bravo FJ; Pullum DA; Orlinger K; Watson EM; Aspoeck A; Fuhrmann G; Guirakhoo F; Monath T; Bernstein DI
Vaccine; 2016 Apr; 34(17):1993-9. PubMed ID: 26973071
[TBL] [Abstract][Full Text] [Related]
12. Vaccine Development for Cytomegalovirus.
Inoue N; Abe M; Kobayashi R; Yamada S
Adv Exp Med Biol; 2018; 1045():271-296. PubMed ID: 29896672
[TBL] [Abstract][Full Text] [Related]
13. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
[TBL] [Abstract][Full Text] [Related]
14. Dominant Antiviral CD8
Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
Front Immunol; 2022; 13():680559. PubMed ID: 35154089
[TBL] [Abstract][Full Text] [Related]
15. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
16. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
17. Preventing Infection by Human Cytomegalovirus.
Plotkin SA
J Infect Dis; 2020 Mar; 221(Suppl 1):S123-S127. PubMed ID: 32134484
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
[TBL] [Abstract][Full Text] [Related]
19. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]